DR. RALPH C. LOOMIS, MD

ASHEVILLE, NC

Research Active
Neurological Surgery NPI registered 21+ years 23 publications 1960 – 2022 NPI: 1699779595
MiceCells, CulturedDisease Models, AnimalMice, KnockoutAntineoplastic AgentsBrainVirus ReplicationApoptosisHIV-1Mice, SCIDTumor Cells, CulturedCell SurvivalLymphoproliferative DisordersMemory DisordersHerpesvirus 4, Human

Practice Location

7 VANDERBILT PARK DR
ASHEVILLE, NC 28803-1700

Phone: (828) 255-7776

What does RALPH LOOMIS research?

Dr. Loomis focuses on the intersection of environmental science and human health, particularly how technology and diseases affect various biological systems. For instance, his research on floating wind turbines explores their impact on marine life, such as the potential for animal entanglement and seabird attraction. In medicine, he investigates conditions like pyoderma gangrenosum following knee surgeries and explores innovative treatments for diseases like HIV and cancer. His work not only aims to understand the complexities of diseases like Zika and the behaviors associated with autism in young children but also examines how newer therapies can enhance existing treatment regimens for various conditions.

Key findings

  • In his 2021 study, Dr. Loomis identified that treatment with steroids significantly improved the condition of a patient with pyoderma gangrenosum after knee replacement surgery, a complication that had been previously unrecognized.
  • His research in 2019 found that the drug rilpivirine reduced Zika virus levels in brain cells of mice by significantly decreasing mortality rates associated with the infection.
  • In a 2019 study on health information exchange systems, Dr. Loomis noted that public health officials saved between $2,312 and $4,624 for chlamydia reporting and treatment in Western New York, streamlining response efforts for STIs.
  • He discovered in a 2008 study that combining the drugs bortezomib and a Bcl-2 inhibitor increased cell death rates in EBV-associated cancers by significantly enhancing treatment efficacy.
  • His 2014 research indicated that toddlers with autism spectrum disorders experienced more difficulties with communication and daily living tasks compared to those with developmental delays.

Frequently asked questions

Does Dr. Loomis study environmental impacts on health?
Yes, he researches how technologies like floating wind turbines can affect marine life and habitats.
What treatments has Dr. Loomis developed or researched?
He has researched innovative treatments for HIV and various cancers, including the effectiveness of drugs like rilpivirine and bortezomib.
Is Dr. Loomis's work relevant to patients with autism?
Yes, he has studied adaptive behaviors in toddlers with autism spectrum disorders, which can inform early intervention strategies.
How does Dr. Loomis's research help patients undergoing surgeries?
His research on complications like pyoderma gangrenosum after knee replacements helps doctors better manage unexpected post-surgery issues.
What does Dr. Loomis find in his studies about Zika virus?
He found that the drug rilpivirine significantly helps reduce Zika virus levels in the brain, leading to better outcomes in affected mice.

Publications in plain English

Potential impacts of floating wind turbine technology for marine species and habitats.

2022

Journal of environmental management

Maxwell SM, Kershaw F, Locke CC, Conners MG, Dawson C +3 more

Plain English
This study looked at how floating wind turbines, which can be placed in deeper waters than traditional turbines, might affect marine life and habitats. Researchers identified possible risks, including marine animals getting tangled in equipment, seabirds being drawn to the turbines, and damage to the seafloor from the turbine structures. They found that using certain configurations, like taut mooring lines, can help reduce these environmental impacts and suggested that more research and monitoring technologies are needed to ensure marine ecosystems remain healthy. Who this helps: This benefits marine animals, environmental managers, and renewable energy developers.

PubMed

Pyoderma Gangrenosum After Bilateral Total Knee Arthroplasty.

2021

Arthroplasty today

Loomis R, Merrit M, Aleshin MA, Graw G, Lee G +1 more

Plain English
This study looked at a 62-year-old man who developed a serious skin condition called pyoderma gangrenosum after having both of his knees replaced in surgery. After experiencing wound issues and not responding to standard treatments, he was diagnosed with this condition, which improved significantly when treated with steroids. Recognizing pyoderma gangrenosum as a possible complication can help doctors better manage similar cases after knee surgeries. Who this helps: This helps patients who undergo knee replacement surgeries and may experience unexpected complications.

PubMed

A longitudinal characterization of sex-specific somatosensory and spatial memory deficits in HIV Tg26 heterozygous mice.

2020

PloS one

Barbe MF, Loomis R, Lepkowsky AM, Forman S, Zhao H +1 more

Plain English
This study looked at memory and sensory problems in a special type of mice that are genetically modified to carry parts of the HIV virus. Researchers found that female mice with this genetic modification had serious issues: they struggled to feel painful heat and performed poorly on memory tests as they aged, with worsening affects from 2.5 months to 10 months old. In contrast, male mice did not show these memory issues, suggesting that the effects of HIV on the brain might be worse for females. Who this helps: This research is important for scientists studying HIV and could help develop better treatments for patients, especially women living with the virus.

PubMed

Quantifying benefits of using health information exchange to support public health STI reporting and treatment in Western New York.

2019

Health information management : journal of the Health Information Management Association of Australia

Haque SN, Territo H, Bailey R, Massoudi B, Loomis R +1 more

Plain English
This study looked at how using a health information exchange (HIE) system can save time and money for public health officials when reporting and treating sexually transmitted infections (STIs) like chlamydia and gonorrhea in Western New York. Researchers found that the HIE helped avoid requests for information, leading to savings of between $2,312 and $4,624 for chlamydia and $809 to $1,512 for gonorrhea, while also streamlining the treatment process. This is important because it allows public health staff to respond more quickly and effectively to STI cases, ultimately improving public health services. Who this helps: This helps public health officials and local health departments manage STIs more efficiently.

PubMed

Suppression of Zika Virus Infection in the Brain by the Antiretroviral Drug Rilpivirine.

2019

Molecular therapy : the journal of the American Society of Gene Therapy

Sariyer IK, Gordon J, Burdo TH, Wollebo HS, Gianti E +12 more

Plain English
This study explored how the drug rilpivirine (RPV), typically used for treating HIV, can fight Zika virus infection in the brain. It found that RPV successfully reduced Zika virus levels in brain cells and improved health outcomes in mice, cutting down mortality rates associated with the virus. In brain regions like the hippocampus and frontal cortex, RPV significantly lowered the amount of Zika RNA present. Who this helps: This helps patients with Zika virus infection and may benefit doctors treating them.

PubMed

Memory deficits, gait ataxia and neuronal loss in the hippocampus and cerebellum in mice that are heterozygous for Pur-alpha.

2016

Neuroscience

Barbe MF, Krueger JJ, Loomis R, Otte J, Gordon J

Plain English
This study looked at mice with a reduced version of a protein called Pur-alpha to understand how it affects their behavior and brain health. The researchers found that these mice showed problems with movement, such as wider steps and missteps, as well as significant memory issues. Specifically, they observed fewer neurons in important brain areas, which can be linked to diseases affecting brain development and function. Who this helps: This research benefits scientists studying brain disorders related to cognitive decline.

PubMed

The comet-like composition of a protoplanetary disk as revealed by complex cyanides.

2015

Nature

Öberg KI, Guzmán VV, Furuya K, Qi C, Aikawa Y +3 more

Plain English
This study looked at the chemical makeup of a disk surrounding a young star, focusing specifically on complex cyanides like methyl cyanide and cyanoacetylene. Researchers found that these compounds are present in similar ratios to those found in comets, suggesting that both simple and complex organic molecules are forming in these disks. This discovery is important because it indicates that the rich chemistry that contributed to the development of life on Earth is also happening in other star systems. Who this helps: This helps scientists studying the origins of life and the conditions needed for life on other planets.

PubMed

Adaptive behavior in toddlers under two with autism spectrum disorders.

2014

Journal of autism and developmental disorders

Paul R, Loomis R, Chawarska K

Plain English
This study looked at the adaptive behavior of 54 toddlers under two years old diagnosed with autism spectrum disorder (ASD) and compared them to 18 toddlers with developmental delays (DD). The researchers found that the ASD group showed more difficulties in various skills measured by a specific assessment, with notable differences primarily in understanding communication and daily living tasks. This research highlights the specific areas where toddlers with ASD struggle, which can guide early intervention strategies to support their development. Who this helps: This benefits parents and caregivers of toddlers with autism, as well as healthcare providers working with young children.

PubMed

Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.

2008

European journal of haematology

Srimatkandada P, Loomis R, Carbone R, Srimatkandada S, Lacy J

Plain English
This study looked at how two treatments, bortezomib and a Bcl-2 inhibitor called HA14-1, work together to kill cancer cells transformed by the Epstein-Barr virus (EBV). Researchers found that bortezomib alone stopped the growth of these cells and triggered their death. When combined with HA14-1, the effects were even stronger, leading to significantly higher rates of cell death and less tumor growth in lab models. This is important because it suggests a new treatment approach for cancers linked to EBV, which could improve outcomes for patients with these conditions. Who this helps: Patients with EBV-associated cancers.

PubMed

Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice.

2006

International journal of cancer

Lacy J, Loomis R, Grill S, Srimatkandada P, Carbone R +1 more

Plain English
This study looked at a new treatment approach for nasopharyngeal carcinoma (NPC), a type of cancer linked to the Epstein-Barr virus (EBV). Researchers found that using a drug called G3139 alongside cisplatin, a common chemotherapy drug, cured 69% of mice with established tumors, compared to 0% for those receiving cisplatin alone. This is important because it shows that targeting the Bcl-2 protein can make standard cancer treatments more effective. Who this helps: This helps patients with nasopharyngeal carcinoma.

PubMed

Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.

2003

Clinical cancer research : an official journal of the American Association for Cancer Research

Loomis R, Carbone R, Reiss M, Lacy J

Plain English
Researchers studied how a treatment called G3139, which targets a protein involved in cell survival (Bcl-2), works alongside the cancer drug rituximab in a type of cancer linked to the Epstein-Barr virus (EBV). They found that when used together, G3139 and rituximab significantly increased the chance of survival in lab animals with this type of cancer, with 79% of treated animals remaining tumor-free for over 160 days, compared to 89% of animals treated with either drug alone that died from cancer. This matters because it suggests a new, effective treatment option for patients with EBV-associated lymphoproliferative diseases, which are often hard to treat. Who this helps: Patients with Epstein-Barr virus-related cancers, such as post-transplant lymphoproliferative disorder (PTLD) and AIDS-related lymphoma.

PubMed

HIV-1 replication and pathogenesis in the human thymus.

2003

Current HIV research

Meissner EG, Duus KM, Loomis R, D'Agostin R, Su L

Plain English
This research paper examines how HIV replicates and damages the thymus, a vital organ for the immune system, in both adults and children. The authors found that HIV affects the thymus by reducing its ability to produce T cells, which are crucial for fighting infections. Understanding these processes helps in finding ways to restore thymus function and improve treatments for HIV patients, ultimately enhancing their immune responses. Who this helps: This helps patients with HIV and their healthcare providers.

PubMed

Stromal-derived factor 1 expression in the human thymus.

2002

Journal of immunology (Baltimore, Md. : 1950)

Zaitseva M, Kawamura T, Loomis R, Goldstein H, Blauvelt A +1 more

Plain English
This study investigated a protein called Stromal-derived factor-1 (SDF-1) in the human thymus, which is important for the development of immune cells. Researchers found that SDF-1 is produced by specific cells in the thymus and helps attract immune cells known as dendritic cells, particularly in conditions such as HIV infection, where these dendritic cells seem to help remove dying cells. Understanding how SDF-1 works is important because it can help improve our knowledge of immune system function and how to address immune-related issues in diseases like HIV. Who this helps: This helps patients with immune system disorders, including those with HIV.

PubMed

Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

2000

Biochemical pharmacology

Finch RA, Liu M, Grill SP, Rose WC, Loomis R +3 more

Plain English
This research studied a drug called Triapine, which blocks a specific enzyme important for cancer cell growth. The researchers found that Triapine effectively fought against certain types of leukemia and other cancers in mice, leading to complete recovery in some cases and better results compared to another drug called hydroxyurea. This is significant because it shows that Triapine could be a more effective treatment option for cancers that are resistant to other therapies. Who this helps: Patients with difficult-to-treat cancers.

PubMed

Cytotoxicity and DNA crosslinks produced by mitomycin analogs in aerobic and hypoxic EMT6 cells.

1991

Cancer communications

Keyes SR, Loomis R, DiGiovanna MP, Pritsos CA, Rockwell S +1 more

Plain English
This study looked at different types of mitomycin antibiotics to see how effective they are at killing tumor cells under normal and low-oxygen conditions. Researchers found that most of the tested antibiotics were better at killing cancer cells when oxygen levels were low, with the compounds causing similar levels of DNA damage across different conditions needed to kill the cells. For instance, one type was particularly potent in low oxygen, while another worked much better with oxygen. Who this helps: This research helps doctors choose the best treatment strategies for patients with tumors that thrive in low-oxygen environments.

PubMed

Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo.

1991

Cancer communications

Rockwell S, Keyes SR, Loomis R, Kelley M, Vyas DM +3 more

Plain English
Researchers studied new versions of two cancer-fighting drugs, mitomycin C and porfiromycin, to see how well they could kill cancer cells in low-oxygen (hypoxic) conditions and normal oxygen levels. They found that a specific new drug called BMY-42355 was particularly effective at killing hypoxic cancer cells while being less harmful to healthy cells, with a better safety record compared to the original drugs. In tests with mice, BMY-42355 worked well both alone and with radiation, showing promise as an effective treatment. Who this helps: This helps cancer patients, especially those with tumors in low-oxygen environments.

PubMed

P31-NMR studies of muscle in patients with venous insufficiency.

1987

International angiology : a journal of the International Union of Angiology

Taheri SA, Pollack L, Loomis R

Plain English
This study examined the muscles of patients with venous insufficiency, a condition where blood does not flow properly in the veins. Researchers used a technique called phosphorus nuclear magnetic resonance to identify changes in muscle biochemistry. They found that the muscles in these patients showed signs of damage related to increased pressure in the veins, which is important for understanding the disease and may lead to better treatments. Who this helps: This helps patients with venous insufficiency by providing insights that could improve their care.

PubMed

Cell-mediated amplification and down regulation of cytotoxic immune response against autologous human cancer.

1987

Journal of immunology (Baltimore, Md. : 1950)

Mukherji B, Guha A, Loomis R, Ergin MT

Plain English
This study looked at how certain immune cells in the body respond to a patient's own cancer cells, specifically a type of tumor called paraganglioma. The researchers found that some helper immune cells could boost the attack on the cancer cells, while other types of T cells could actually reduce that immune response. This dual effect shows that the immune system can both enhance and suppress its response to the same cancer, which is important for developing new cancer treatments. Who this helps: This research benefits patients with cancer by improving our understanding of how their immune system interacts with their tumors.

PubMed

Experimental studies on the replication and dissemination of Qalyub virus (Bunyaviridae: Nairovirus) in the putative tick vector, Ornithodoros (Pavlovskyella) erraticus.

1985

The American journal of tropical medicine and hygiene

Miller BR, Loomis R, Dejean A, Hoogstraal H

Plain English
This study investigated whether the Ornithodoros (Pavlovskyella) erraticus tick can carry and spread the Qalyub virus. Researchers found that 67 out of 205 ticks (about 33%) were able to become infected with the virus after feeding on infected mice, and the virus remained detectable in them for up to 179 days. Understanding how this tick can transmit the Qalyub virus is important for developing strategies to control the spread of this virus, which can affect animal and human health. Who this helps: This research helps public health officials, veterinary scientists, and patients at risk from the Qalyub virus.

PubMed

Animal models of neuropsychiatric disorders and their relevance for Tourette syndrome.

1982

Advances in neurology

Shaywitz BA, Wolf A, Shaywitz SE, Loomis R, Cohen DJ

PubMed

Effects of sodium pentobarbital on the radiation response of EMT6 cells in vitro and EMT6 tumors in vivo.

1980

Radiation research

Rockwell S, Loomis R

PubMed

Use of ileal segments in urology.

1961

The Journal of urology

HODGES CV, LEHMAN TH, MOORE RJ, LOOMIS R

PubMed

Use of ileal segments in urology.

1960

Transactions. American Urological Association. Western Section

HODGES CV, LEHMAN TH, MOORE RJ, LOOMIS R

PubMed

Frequent Co-Authors

Jennifer Gordon Rocco Carbone Jill Lacy A C Sartorelli S Rockwell Mary F Barbe Pavani Srimatkandada S R Keyes C V HODGES T H LEHMAN

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.